{
    "data": [
        {
            "id": "69a1aab024c37e0001bbfa56",
            "title": "Trump Media Explores Truth Social Spin-Off",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Trump Media &amp; Technology Group Corp.</strong> <strong><a href=\"https://www.benzinga.com/quote/DJT\" rel=\"noreferrer noopener\" target=\"_blank\"></a><a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"DJT\" href=\"https://www.benzinga.com/quote/DJT\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/DJT\" target=\"_blank\">DJT</a>)</strong> stock rose Friday as the company is <a href=\"https://www.benzinga.com/pressreleases/26/02/g50925423/trump-media-technology-group-tae-technologies-and-texas-ventures-acquisition-iii-announce-discussi\" rel=\"noreferrer noopener\" target=\"_blank\">engaged in ongoing discussions</a> regarding a potential spin-off.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The spin-off would distribute shares to TMTG shareholders prior to the merger with TAE, with the aim of creating distinct strategies for the newly formed companies.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Core Assets To Be Retained</h2><!--/$--><!--$--><p class=\"block core-block\">Under the latest development, TMTG’s existing businesses and assets would remain with the current public company after the spin-off. The merger is intended to combine TMTG’s robust balance sheet with TAE’s leading technologies, although no definitive agreement has been reached yet.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Truth Social America First ETF</h2><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">The Truth Social Funds and their existing ETF series operate under the Truth.Fi fintech brand of Trump Media &amp; Technology Group, which runs Truth Social and Truth+. Under the deal, the Point Bridge America First ETF will be reorganized and renamed as the Truth Social America First ETF.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">DJT Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">DJT stock is currently trading 10.5% below its 20-day simple moving average (SMA) and 12.3% below its 100-day SMA, indicating short-term weakness. Shares have decreased 61.1% over the past 12 months and are currently positioned closer to their 52-week lows than highs.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.05, below its signal line at 0.10, indicating bearish pressure on the stock.</p><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $11.00</li>\n<li><strong>Key Support</strong>: $9.50</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Earnings &amp; Analyst Outlook</h2><!--/$--><!--$--><p class=\"block core-block\">The countdown is on: Trump Media &amp; Technology Group is set to report earnings on March 10, 2026.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>EPS Estimate</strong>: 1 cent (Down from 1 cent YoY)</li>\n<li><strong>Revenue Estimate</strong>: $1.00 Million (Down from $1.00 Million YoY)</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>DJT Price Action:</strong> Trump Media shares were up 1.55% at $11.13 during premarket trading on Friday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Piotr Swat via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50927621\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Konskie--Poland---February-27--2025-Trum.jpeg",
            "link": "https://www.benzinga.com/markets/equities/26/02/50927621/trump-media-explores-truth-social-spin-off",
            "pub_date": "2026-02-27 22:31:08",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1aa6b24c37e0001bbfa23",
            "title": "Frontline Q4 Earnings Summary &amp; Key Takeaways",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Frontline</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FRO\" target=\"_blank\">FRO</a>) reported its Q4 earnings results on Friday, February 27, 2026 at 02:00 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's what investors need to know about the announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Frontline beat estimated earnings by 0.98%, reporting an EPS of $1.03 versus an estimate of $1.02.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was up $198.86 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Previous Earnings Records</h3><!--/$--><!--$--><p class=\"block core-block\">Last quarter the company missed on EPS by $0.06 which was followed by a 3.64% increase in the share price the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Frontline's past performance:</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Frontline <a href=\"https://www.benzinga.com/quote/FRO/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_6.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50927548/frontline-q4-earnings-summary-key-takeaways",
            "pub_date": "2026-02-27 22:30:07",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1aa7a24c37e0001bbfa31",
            "title": "If You Invested $100 In Vale Stock 10 Years Ago, You Would Have This Much Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Vale (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/VALE\" target=\"_blank\">VALE</a>) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 15.46%. Currently, Vale has a market capitalization of $73.51 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In VALE:</strong> If an investor had bought $100 of VALE stock 10 years ago, it would be worth <strong>$476.86</strong> today based on a price of $17.22 for VALE at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">Vale's Performance Over Last 10 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50927563/if-you-invested-100-in-vale-stock-10-years-ago-you-would-have-this-much-today",
            "pub_date": "2026-02-27 22:30:22",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1a71624c37e0001bbf8d0",
            "title": "Here&#39;s How Much $100 Invested In Axon Enterprise 5 Years Ago Would Be Worth Today",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Axon Enterprise (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AXON\" target=\"_blank\">AXON</a>) has outperformed the market over the past 5 years by 14.79% on an annualized basis producing an average annual return of 27.06%. Currently, Axon Enterprise has a market capitalization of $43.31 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In AXON:</strong> If an investor had bought $100 of AXON stock 5 years ago, it would be worth <strong>$324.31</strong> today based on a price of $545.17 for AXON at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">Axon Enterprise's Performance Over Last 5 Years</h3><!--/$--><!--$?--><template id=\"B:1\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/26/02/50927220/heres-how-much-100-invested-in-axon-enterprise-5-years-ago-would-be-worth-today",
            "pub_date": "2026-02-27 22:15:54",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1a77d24c37e0001bbf922",
            "title": "Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Amneal Pharmaceuticals Inc. </strong><a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"AMRX\" href=\"https://www.benzinga.com/quote/AMRX\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/AMRX\" target=\"_blank\">AMRX</a>)<!-- --> released its <a href=\"https://www.benzinga.com/pressreleases/26/02/g50921160/amneal-reports-fourth-quarter-and-full-year-2025-financial-results\" rel=\"noreferrer noopener\" target=\"_blank\">recent financial results</a> announcement on Friday.</p><!--/$--><!--$--><p class=\"block core-block\">Amneal Pharmaceuticals announced its fourth-quarter revenue of $814.32 million, an 11% increase year over year, beating the <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of $807.89 million</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The generic drug maker reported adjusted earnings of 21 cents, beating the Wall Street estimate of 18 cents.</p><!--/$--><!--$--><p class=\"block core-block\">In the fourth quarter, adjusted EBITDA reached $175 million, reflecting a 13% increase year-over-year.</p><!--/$--><!--$--><p class=\"block core-block\">The company highlighted the strong uptake of its specialty products, particularly CREXONT, while also noting a robust cadence of new product approvals in its Affordable Medicines segment.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">Amneal Pharmaceuticals expects fiscal 2026 adjusted earnings between 93 cents and $1.03, compared to the <a href=\"https://www.benzinga.com/calendars/guidance\" rel=\"noreferrer noopener\" target=\"_blank\">consensus of 94 cents</a>.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects 2026 sales of $3.05-$3.15 billion versus the consensus of $3.21 billion.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects adjusted EBITDA of $720 million-$760 million, with operating cash flow of $325 million-$375 million.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Technical Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">The stock is currently trading 5.2% below its 20-day simple moving average (SMA) and 6.8% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have increased by 16%, and they are currently positioned closer to their 52-week highs than lows, suggesting a generally positive trend.</p><!--/$--><!--$--><p class=\"block core-block\">The RSI is at 50.00, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Key Resistance</strong>: $15.00</li>\n<li><strong>Key Support</strong>: $13.00</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Consensus &amp; Recent Actions:</strong> The stock carries a Buy Rating with an <a href=\"https://www.benzinga.com/quote/NASDAQ:AMRX/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">average price target</a> of $11.83. Recent analyst moves include:</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>Barclays</strong>: Initiated with Overweight (Target $15.00) (Dec. 9, 2025)</li>\n</ul><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>AMRX Price Action:</strong> Amneal Pharmaceuticals shares were up 0.76% at $14.60 during premarket trading on Friday, according to <a href=\"https://pro.benzinga.com/dashboard\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Martin Gregor via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50927300\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Pill-Bottle-And-Pills-On-Blue-Background.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50927300/generic-drugs-focused-amneal-pharmaceuticals-revenue-crosses-800-million",
            "pub_date": "2026-02-27 22:17:36",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}